Background:Co-administration of opioid agonists and antagonists at low doses has been reported to significantly enhance and/or prolong the analgesic effects and reduce or prevent tolerance to or dependence on opioids.
Objectives:The current study aimed at evaluating the naloxone effect on morphine-induced histopathological and hematologic changes in rats.
Materials and Mehods:Thirty mature male Wistar rats were categorized into three groups (n = 10) in a random manner, including the control group receiving normal saline, the morphine-sole group receiving morphine (5 mg/kg/day), and morphine + naloxone group receiving morphine and naloxone (5 and 0.4 mg/kg/day, respectively). After 50 days, the levels of alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglyceride (TG), aspartate aminotransferase (AST), cholesterol, and high-density lipoprotein (HDL) were measured in the serum. Moreover, the levels of superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), and glutathione peroxidase (GPx) were measured to assess the serum antioxidant capacity. Histopathological changes were investigated via hematoxylin and eosin, Masson’s trichrome, and periodic acid-Schiff staining. Inter-group comparisons were made by GraphPad Prism software using one-way ANOVA and Tukey’s test.
Results:The animals in the morphine + naloxone group showed higher AST, ALP, ALT, and CAT levels in comparison with the control and morphine-sole groups (P < 0.05). Our findings revealed no changes in the cholesterol, TG, SOD, and GPx levels among the groups (P > 0.05). However, the morphine-sole group exhibited higher serum levels of HDL compared with the controls (P < 0.05). The morphine-sole group showed fibrosis, local necrosis, immune cell infiltration, and diminished intra-cytoplasmic carbohydrate storage.
Conclusions:The findings suggest that apart from unchanged serum markers, morphine can potentially induce hepatotoxicity, and at the same time, naloxone is able to ameliorate morphine-induced histopathological damages.
Opioids are widely used as potentially effective narcotic analgesics for pain management. The liver is the main organ for morphine biotransformation and/or metabolism (1). Morphine is rapidly metabolized in the liver and leads to direct and/or indirect cytotoxicity, immunoreactivity, oxidative stress, and oncogenic alterations (2). A high dose of morphine (45 - 50 mg/kg) could potentially increase the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) content in the plasma 4 - 5 h post-administration (3).
In line with earlier research, most recent studies on animal models have shown that morphine at different concentrations can significantly affect the plasma levels of inflammatory biomarkers, such as ALT, alkaline phosphatase (ALP), and AST (4-7). For instance, morphine can potentially induce hepatotoxic derangement when administrated at weekly increasing doses. In another study by Samarghandian et al. (4), morphine, under the aforementioned conditions, could relatively up-regulate the serum levels of ALT and AST in rats.
Morphine triggers the formation of reactive oxygen species (ROS) and free radicals and results in oxidative stress in the liver (8-10). Morphine also increases the apoptosis of hepatocytes through inducing severe oxidative stress (11). In addition, chronic administration of morphine changes the serum levels of triglyceride (TG), cholesterol, urea, and glucose under normal and inflammatory conditions (12). However, concurrent use of opioid agonists with opioid antagonists (at low doses) has been reported to significantly increase the analgesic efficacy and perhaps reduce or thwart tolerance and dependence. Similarly, naloxone at low doses can potentially bind to opioid receptors (13-15).
According to a previous study, the prevalence of nausea during postoperative treatment reduced in groups receiving an admixture of morphine and naloxone (16).
The present study aimed at characterizing the effects of naloxone on morphine-mediated cytotoxicity. For this purpose, the serum levels of AST, ALP, and ALT were measured to identify the effects of naloxone on morphine-induced hepatic inflammation. Moreover, by measuring the oxidative stress markers of serum, including catalase (CAT), superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione peroxidase (GPx), the protective effects of naloxone on oxidative stress were examined following morphine administration. Finally, hematologic factors, including serum low-density lipoprotein (LDL), TG, and cholesterol, as well as liver histopathological changes, were studied to determine whether naloxone can inhibit morphine-induced histopathological and hematologic changes.
3. Materials and Methods
Morphine sulfate (10 mg/mL) was provided by Daropakhsh Co. (Tehran, Iran) and naloxone hydrochloride by Caspiantamin Co. (Tehran, Iran). The commercial kits for assessing the levels of TG, cholesterol, HDL, ALP, ALT, and AST were purchased from Pars Azmoon Co. (Tehran, Iran). Also, the commercial kits for SOD and GPx (Ransel and Ransod) were provided by Randox (BT29, Crumlin, UK). Cayman Chemical (Ann Arbor, MI, USA) provided the CAT assay kit, and other chemicals were commercial products of an analytical grade.
3.2. Experimental Animals
Male Wistar rats (230 g - 260 g) were accommodated in standard cages with suitable ventilation and temperature in a 12:12 h dark-light cycle. With free access to standard diet and water, they were accustomed to the laboratory conditions for two weeks. All animals were handled humanely based on ethical guidelines, protocols, and procedures of animal experimentation. The local committee for safety and careful handling of animals also approved the protocol (approval code: IR.UMSU.Rec.1395.211).
3.3. Animal Groups and Treatment Protocol
Thirty mature male Wistar rats were categorized into three groups (n = 10) in a random manner: control group (group 1) receiving normal saline, morphine-sole group (group 2) receiving morphine (5 mg/kg/day), and morphine + naloxone group (group 3) receiving morphine and naloxone (5 and 0.4 mg/kg/day, respectively) (17, 18). All chemicals were administered subcutaneously for 50 consecutive days. Finally, the rats were euthanized following anesthesia with xylazine (5 mg/kg; intraperitoneally (IP)) and ketamine (40 mg/kg; IP) (Alfasan, Woerden, Netherlands) (19).
3.4. Collection of Blood and Tissue Samples
Following euthanasia, blood samples from the heart were immediately collected. Next, serum samples were prepared by centrifugation for 15 min at 3500 rpm and stored at -20°C. Moreover, a midline incision was made, and liver samples were dissected under controlled conditions. Finally, they were fixed in formalin 10% for 72 h.
3.5. MDA and Antioxidant Capacity Assessment
The serum MDA level was assessed based on the thiobarbituric acid reaction (CAS 504-17-6, Merck, Germany) (20), and serum levels of SOD and GPx were evaluated according to the kit protocols.
3.6. Assessment of ALT, AST, HDL, and ALP Levels
The serum levels of ALT, AST, HDL, ALP, cholesterol, and TG were evaluated based on Pars Azmoon commercial kits’ instructions.
3.7. Histological Examination
Previously fixed tissues were dehydrated with ascending degrees of alcohol and paraffin-embedded. Next, histological sections (5 µm) were cut using a rotary microtome (model: 2218 HistoRange, Sweden), and hematoxylin and eosin staining was carried out. The periodic acid-Schiff (PAS) staining method was also used to analyze changes in the intra-cytoplasmic carbohydrate storage (21). Moreover, Masson’s trichrome staining, a specific staining method for collagens, was conducted to investigate possible liver fibrosis (22). Finally, the sections were analyzed under a light microscope (Olympus, BH2, Japan) equipped with an onboard camera (Cyber-Shot, Zeiss, Japan).
The images were entered in Adobe Photoshop CS10 (Adobe System Inc., CA, USA). Pixel-based analyses were run using Image-Pro-Insight version 9.00 (Media Cybernetics, Rockville, USA). Histopathological changes were scored as follows: 0: no change, 1 + : faint change, 2 + : moderate change, 3 + : moderate to intensive change, and 4 + : intensive change. Moreover, all histological analyses were performed by one examiner.
3.8. Data Analysis
Values are presented as mean ± SEM. GraphPad Prism version 7.0 was used for one-way ANOVA and Tukey’s test for inter-group comparisons. The level of significance was set at 0.05.
4.1. Effect of Naloxone on Morphine-Induced Changes in HDL, TG and Cholesterol Levels
The results showed that the experimental groups (morphine-sole and morphine + naloxone) were not significantly different from the controls in terms of most parameters (P > 0.05). The statistical analysis indicated no significant difference between the morphine-sole and morphine + naloxone groups (P > 0.05). However, the morphine + naloxone group showed significantly lower levels of serum HDL (26.50 ± 9.47 mg/dl) compared with the morphine-sole group (67.85 ± 8.30 mg/dl; P < 0.05), while there was no significant difference between the control group (P > 0.05; Figure 1).
4.2. Effect of Naloxone on Hepatic Enzyme Activities
The effects of morphine-sole and morphine + naloxone treatments on the serum levels of hepatic enzymes were assessed biochemically (Figure 2). No significant difference was observed in the serum AST, ALT, or ALP levels between the morphine-sole and control groups (P > 0.05). However, the serum levels of these parameters significantly improved when morphine was co-administrated with naloxone (morphine + naloxone group).
4.3. Effect of Naloxone on Antioxidant Markers
The morphine-sole (7.96 ± 1.73 nmol/min/r) and morphine + naloxone (23.75 ± 5.69 nmol/min/r) groups had significantly higher serum CAT content in comparison with the controls (1.73 ± 0.78 nmol/min/r; P < 0.05). The morphine + naloxone group exhibited a more significant up-regulation. However, no significant differences were found in the serum GPx or SOD between the experimental (morphine-sole and morphine + naloxone) and control groups (Figure 3).
4.4. Protective Effects of Naloxone Against Morphine-Induced Histopathological Changes
The light microscopic analysis indicated the normal distribution of intact hepatocytes, with one or two normal spherical-shaped nuclei in the control group. Moreover, the central veins showed a circular outline. However, morphine-sole treatment resulted in severe central vein dilation and immune cell infiltration in perivascular connective tissues. Also, degenerative nuclei, unrecognizable degenerated cells, and hepatic necrosis were detected in the morphine-sole group. In contrast, cross-sections collected from the morphine + naloxone group exhibited remarkable amelioration of histopathological changes. Therefore, nuclei degeneration, immune cell infiltration, central vein dilation, and local necrosis significantly decreased in the morphine + naloxone group (Figures 4A and B).
4.5. Effect of Naloxone on Morphine-Induced Fibrosis
The cross-sections collected from the morphine-sole group showed intense fibrosis. On the other hand, naloxone could fairly ameliorate morphine-induced fibrosis. Accordingly, cross-sections collected from the morphine + naloxone group showed significantly lower collagen deposition compared with the morphine-sole group (not shown).
4.6. Effect of Naloxone on Intrahepatocellular Carbohydrate Deposition
For examining the effects of morphine-sole and naloxone treatment on the intrahepatocellular carbohydrate deposition, the PAS staining technique was used, and the PAS+ reaction was estimated based on software analyses. Our observations demonstrated significantly lower intracellular carbohydrate accumulation in the morphine-sole group than the controls. However, co-administration of naloxone (morphine + naloxone) remarkably amplified the morphine-induced carbohydrate withdrawal (Figure 5A and B). In order to minimize visual errors, pixel-based intensity analysis was conducted. Animals in the morphine-sole group showed significantly lower PAS+ reaction intensity compared with the control and morphine + naloxone groups.
Our findings demonstrated that naloxone + morphine co-administration significantly decreased the morphine-mediated increase in HDL content. However, no significant changes were found in the serum cholesterol and TG levels in the groups. Also, the serum ALT, AST, and ALP levels increased in the morphine + naloxone group. Naloxone significantly up-regulated the serum CAT level, while the serum levels of MDA, SOD, and GPx did not significantly change in the morphine-sole and morphine + naloxone groups. Finally, morphine administration resulted in immune cell infiltration, nuclei degeneration, vasodilation, necrosis, and fibrosis in liver tissues. Although naloxone had no effects on serum parameters, it could fairly inhibit morphine-induced histopathological damages (23, 24).
Morphine can temporarily diminish blood pressure while up-regulating the level of blood glucose and most blood lipids in a time-dependent manner. Moreover, the long-term use of morphine negatively affects these parameters and initiates and/or promotes aggravated diabetes, dyslipidemia, and hypertension (25, 26). It should be noted that morphine indirectly reduces stomach-intestine movement and affects the homeostasis of cholesterol and HDL through this mechanism leading to fatty liver and corticosterone secretion (12).
In this study, we evaluated hematological factors, including serum lipid profile. The morphine-treated animals showed significantly up-regulated serum levels of HDL, while the serum cholesterol and TG did not change significantly compared with the controls. In contrast, the morphine + naloxone group showed a significant decrease in the serum HDL level, with no change in other parameters. Therefore, we can suggest that 0.4 mg/kg/day of naloxone, when co-administrated with morphine (5 mg/kg/day), can converse the morphine-induced effects on the serum HDL level. In other words, morphine (at least at the administrated dose) does not affect the serum cholesterol and TG levels, while it can up-regulate the serum HDL level, possibly due to disruption in HDL hemostasis.
On the other hand, based on our findings, we can suggest that naloxone (even at the mentioned dose) could down-regulate the morphine-induced increase in HDL, possibly due to the amelioration of HDL homeostasis. Earlier studies have shown that morphine increases the serum cholesterol level in animals with inflammatory conditions compared with normal and healthy animals (12). Concerning cholesterol and TG levels, since animals in this study were physiologically intact and no experimental inflammation was considered, morphine and naloxone did not affect the serum TG or cholesterol.
Considering the stimulatory effects of morphine on inflammatory enzyme activities in the liver, we measured the serum ALP, AST, and ALT levels. Biochemical analyses indicated a slight increase in the serum ALP, AST, and ALT levels in the morphine-sole group, which was insignificant. Naloxone caused a significant increase in the serum levels of hepatic enzymes than the morphine-sole and control groups. Our findings regarding the effect of morphine on the serum levels of these enzymes are contrary to previous reports indicating the stimulatory effect of morphine on ALP, AST, and ALT activities (27-29).
It should be noted that the administrated dose of morphine in the current study was lower (5 mg/kg/day) in comparison with other investigations (10 and 20 mg/kg). Therefore, concerning the lower dose of morphine in our study, we can suggest that higher doses of morphine and/or longer exposure are necessary to characterize the impact of morphine on inflammatory enzymes. The exact naloxone-mediated effects on inflammatory enzymes should be evaluated in future studies. Based on our results, these two agents could exert synergic effects on hepatic inflammatory enzyme activities, at least at the administered doses (5 and 0.4 mg/kg/day of morphine and naloxone, respectively).
According to several reports, acute and chronic morphine exposures may result in oxidative stress by down-regulating the activities of SOD, CAT, and GPx (30, 31). For evaluating the possible effects of naloxone and morphine co-treatment on the serum levels of antioxidant enzymes, we evaluated the levels of GPx, SOD, and CAT. According to the results, neither morphine nor naloxone could affect GPx or SOD. However, naloxone in the morphine + naloxone group could significantly up-regulate the serum CAT levels.
Additionally, the serum level of MDA was evaluated in the current study. Our findings indicated a higher MDA content in the morphine-sole group in comparison with the morphine + naloxone group. Although these differences were not statistically significant, morphine could potentially up-regulate lipid peroxidation, and an increase in dose and/or exposure time would fairly imbalance the antioxidant and oxidant systems. We also showed that naloxone could improve the antioxidant activity, at least by up-regulating the CAT level.
According to previous findings, chronic and acute exposures to morphine potentially result in hepatotoxicity, immunoreactivity, and genotoxic damages (2, 4). Therefore, we investigated the histopathological changes in the liver. The light microscopic analyses showed that naloxone in the morphine + naloxone group significantly ameliorated the morphine-induced nuclear degeneration, necrosis, fibrosis, vasodilation, and immune cell infiltration. Moreover, we found a significant intra-hepatocellular carbohydrate withdrawal in the morphine-sole group. According to previous reports, morphine is able to enhance the blood glucose level (12, 23, 24). Therefore, it can be suggested that morphine up-regulates blood glucose by discharging the hepatic carbohydrate content; severe carbohydrate withdrawal confirms this theory.
Overall, although chronic exposure to morphine (5 mg/kg/day) did not significantly change the serum antioxidant and hepatic enzyme levels, it could fairly induce hepatotoxic effects. Therefore, serum markers, including antioxidant enzymes, hepatic enzymes, and lipid profiles (cholesterol and TG) are not appropriate parameters to confirm the possible adverse effects of morphine on liver tissues. Moreover, naloxone, even at the administrated dose in this study, was able to protect liver tissues against morphine-induced damage, apart from its boosting effect on hepatic enzyme activities.
Our findings showed that morphine and naloxone co-treatment did not change the level of serum markers, such as GPx, SOD, cholesterol, and TG in rats. Meanwhile, naloxone, when co-administrated with morphine, could reduce the morphine-induced increase in HDL level and up-regulate hepatic enzyme activity. Moreover, it was found that apart from unchanged serum markers, morphine could potentially induce hepatotoxicity, and at the same time, naloxone was able to ameliorate morphine-induced histopathological damages. Based on our findings, it can be suggested that serum markers do not fully represent the detrimental effects of morphine and ameliorative effects of naloxone on liver tissues. However, further studies are needed to uncover the precise mechanism of naloxone effects on morphine-induced hepatotoxicity at cellular and molecular levels.
Mohammadi N, Bayati V, Nejatbakhsh R, Heidari MH, Dadpay M, Tavassol A. Effect of oral morphine on the liver of Wistar rat fetuses in the second week of development: a histopathological study. RJMS. 2015;21(129):1-9.
Mikus G, Klimas R. Relative contribution of morphine and morphine-6-glucuronide to the analgesic effect after morphine administration. Br J Anaesth. 2015;114(6):1007. doi: 10.1093/bja/aev132. [PubMed: 25991747].
Gurantz D, Correia MA. Morphine-mediated effects on rat hepatic heme and cytochrome P-450 in vivo: antagonism by naloxone in the liver. Biochem Pharmacol. 1981;30(12):1529-36. [PubMed: 6895031].
Samarghandian S, Afshari R, Farkhondeh T. Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver. Int J Clin Exp Med. 2014;7(5):1449-53. [PubMed: 24995110]. [PubMed Central: PMCPmc4073771].
Xu B, Wang Z, Li G, Li B, Lin H, Zheng R, et al. Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. Basic Clin Pharmacol Toxicol. 2006;99(2):153-61. doi: 10.1111/j.1742-7843.2006.pto_461.x. [PubMed: 16918717].
Pinelli A, Cighetti G, Trivulzio S. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration. Fundam Clin Pharmacol. 2008;22(4):439-45. doi: 10.1111/j.1472-8206.2008.00612.x. [PubMed: 18705754].
Lee YJ, Zhao RJ, Kim YW, Kang SJ, Lee EK, Kim NJ, et al. Acupuncture inhibits liver injury induced by morphine plus acetaminophen through antioxidant system. European Journal of Integrative Medicine. 2016;8(3):204-12. doi: 10.1016/j.eujim.2015.12.009.
Zhang YT, Zheng QS, Pan J, Zheng RL. Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. Basic Clin Pharmacol Toxicol. 2004;95(2):53-8. doi: 10.1111/j.1742-7843.2004.950202.x. [PubMed: 15379780].
Sumathi T, Nathiya VC, Sakthikumar M. Protective Effect of Bacoside-A against Morphine-Induced Oxidative Stress in Rats. Indian J Pharm Sci. 2011;73(4):409-15. eng. doi: 10.4103/0250-474x.95624. [PubMed: 22707825]. [PubMed Central: PMCPmc3374557].
Lan X, Rai P, Chandel N, Cheng K, Lederman R, Saleem MA, et al. Morphine induces albuminuria by compromising podocyte integrity. PLoS One. 2013;8(3). e55748. doi: 10.1371/journal.pone.0055748. [PubMed: 23555556]. [PubMed Central: PMCPmc3612045].
Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010;212(2):193-203. doi: 10.1007/s00213-010-1942-4. [PubMed: 20665209]. [PubMed Central: PMCPmc2939200].
Chahkandi M, Askari N, Asadikaram G. The Effect of Acute and Chronic Morphine on Some Blood Biochemical Parameters in an Inflammatory Condition in Gonadectomized Male Rats. Addict Health. 2015;7(3-4):130-9. [PubMed: 26885349]. [PubMed Central: PMCPmc4741233].
Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology. 2003;99(1):148-51. [PubMed: 12826854].
Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84(2-3):121-31. [PubMed: 10666516].
Burns L, Wang H. Ultra-Low-Dose Naloxone or Naltrexone to Improve Opioid Analgesia: The History, the Mystery and a Novel Approach. 2. 2010. doi: 10.4137/CMT.S4870.
Yeh YC, Lin TF, Wang CH, Wang YP, Lin CJ, Sun WZ. Effect of combining ultralow-dose naloxone with morphine in intravenous patient-controlled analgesia: the cut-off ratio of naloxone to morphine for antiemesis after gynecologic surgery. J Formos Med Assoc. 2008;107(6):478-84. doi: 10.1016/s0929-6646(08)60156-4. [PubMed: 18583219].
Payabvash S, Beheshtian A, Salmasi AH, Kiumehr S, Ghahremani MH, Tavangar SM, et al. Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci. 2006;79(10):972-80. doi: 10.1016/j.lfs.2006.05.008. [PubMed: 16750225].
Cochin J, Kornetsky C. Development and loss of tolerance to morphine in the rat after single and multiple injections. Journal of Pharmacology and Experimental Therapeutics. 1964;145(1):1-10.
Mahdivand N, Najafi G, Nejati V, Shalizar‐Jalali A, Rahmani F. Royal jelly protects male rats from heat stress‐induced reproductive failure. Andrologia. 2019;51(3). e13213.
Olszewska-Slonina DM, Matewski D, Czajkowski R, Olszewski KJ, Wozniak A, Odrowaz-Sypniewska G, et al. The concentration of thiobarbituric acid reactive substances (TBARS) and paraoxonase activity in blood of patients with osteoarthrosis after endoprosthesis implantation. Med Sci Monit. 2011;17(9):Cr498-504. [PubMed: 21873946]. [PubMed Central: PMCPmc3560525].
Hui H, Ma W, Cui J, Gong M, Wang Y, Zhang Y, et al. Periodic acid‑Schiff staining method for function detection of liver cells is affected by 2% horse serum in induction medium. Molecular medicine reports. 2017;16(6):8062-8. doi: 10.3892/mmr.2017.7587. [PubMed: 28944920].
Liu F, Cao X, Ye J, Pan X, Kan X, Song Y. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer: A case report. Mol Clin Oncol. 2018;8(3):453-6. doi: 10.3892/mco.2017.1540. [PubMed: 29468059]. [PubMed Central: PMCPmc5791411].
Nagamatsu K, Ohno Y, Ikebuchi H, Takahashi A, Terao T, Takanaka A. Morphine metabolism in isolated rat hepatocytes and its implications for hepatotoxicity. Biochem Pharmacol. 1986;35(20):3543-8. [PubMed: 2429666].
Najafipour H, Beik A. The Impact of Opium Consumption on Blood Glucose, Serum Lipids and Blood Pressure, and Related Mechanisms. Front Physiol. 2016;7:436. doi: 10.3389/fphys.2016.00436. [PubMed: 27790151]. [PubMed Central: PMCPmc5061814].
Sadeghian S, Boroumand MA, Sotoudeh-Anvari M, Rabbani S, Sheikhfathollahi M, Abbasi A. Effect of opium on glucose metabolism and lipid profiles in rats with streptozotocin-induced diabetes. Endokrynol Pol. 2009;60(4):258-62. [PubMed: 19753539].
Salahshoor M, Mohamadian S, Kakabaraei S, Roshankhah S, Jalili C. Curcumin improves liver damage in male mice exposed to nicotine. J Tradit Complement Med. 2016;6(2):176-83. doi: 10.1016/j.jtcme.2014.11.034. [PubMed: 27114942]. [PubMed Central: PMCPmc4833467].
Salahshoor MR, Roshankhah S, Hosseni P, Jalili C. Genistein Improves Liver Damage in Male Mice Exposed to Morphine. Chin Med J (Engl). 2018;131(13):1598-604. doi: 10.4103/0366-6999.235117. [PubMed: 29941714]. [PubMed Central: PMCPmc6032674].
Shahraki MR, Shahraki E, Mirshekari H, Shahraki AR. Morphine Sulphate Toxicity on Liver Function Tests in Fructose-Induced Insulin Resistant Male Rats. Zahedan J Res Med Sci. 2014;16(2):50-3.
Abdel-Zaher AO, Abdel-Rahman MS, E. Lwasei FM. Blockade of nitric oxide overproduction and oxidative stress by Nigella sativa oil attenuates morphine-induced tolerance and dependence in mice. Neurochem Res. 2010;35(10):1557-65. doi: 10.1007/s11064-010-0215-2. [PubMed: 20552271].
Zhou J, Li Y, Yan G, Bu Q, Lv L, Yang Y, et al. Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress. Neurotox Res. 2011;20(4):334-42. doi: 10.1007/s12640-011-9247-x. [PubMed: 21611853].